The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
New real-world proof means that remedy alternative might make a significant distinction for sufferers dwelling with metastatic castration-sensitive prostate most cancers (mCSPC),...
Minimal residual illness, or MRD, testing can supply psychological consolation to sufferers with breast most cancers and survivors in addition to perception...
The U.S. Meals and Drug Administration (FDA) has granted quick observe designation to IBI3003, an anti-GPRC5D/BCMA/CD3 tri-specific antibody, to expedite the event...
